Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
EZH2 inhibitors enhance effectiveness of cancer immunotherapies

EZH2 inhibitors enhance effectiveness of cancer immunotherapies

Innovative approach predicts most effective medication for cancer patients

Innovative approach predicts most effective medication for cancer patients

New study explores obecabtagene autoleucel for adults with hard-to-treat leukemia

New study explores obecabtagene autoleucel for adults with hard-to-treat leukemia

Scientists identify drug-resistant bone marrow cells linked to poor outcomes in fast-growing leukemia

Scientists identify drug-resistant bone marrow cells linked to poor outcomes in fast-growing leukemia

Obe-cel demonstrates strong efficacy and safety in treating leukemia

Obe-cel demonstrates strong efficacy and safety in treating leukemia

Epigenetic profiles of blood cancer cells could aid in diagnosis and treatment

Epigenetic profiles of blood cancer cells could aid in diagnosis and treatment

Multiomic signatures identified for rapid detection and treatment of high-risk T-ALL

Multiomic signatures identified for rapid detection and treatment of high-risk T-ALL

Could medical imaging innovation be the catalyst for precision medicine?

Could medical imaging innovation be the catalyst for precision medicine?

Nanoparticle coating enhances cancer drug delivery and reduces side effects

Nanoparticle coating enhances cancer drug delivery and reduces side effects

Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients

Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients

Study links cannabis use to genotoxicity and transgenerational health impacts

Study links cannabis use to genotoxicity and transgenerational health impacts

Engineered virus-like particles evolve for superior gene delivery efficiency

Engineered virus-like particles evolve for superior gene delivery efficiency

Stand Up To Cancer partners with Johnson & Johnson to explore new treatment for AL amyloidosis

Stand Up To Cancer partners with Johnson & Johnson to explore new treatment for AL amyloidosis

New discovery could lead to better treatments for drug-resistant leukemia

New discovery could lead to better treatments for drug-resistant leukemia

MD Anderson launches new institute for advancing cell therapy

MD Anderson launches new institute for advancing cell therapy

CRISPR technology reveals essential noncoding RNAs in the human genome

CRISPR technology reveals essential noncoding RNAs in the human genome

Gene editing with CRISPR may introduce new defects

Gene editing with CRISPR may introduce new defects

Weill Cornell Medicine teams receive funding from Starr Cancer Consortium

Weill Cornell Medicine teams receive funding from Starr Cancer Consortium

Research uncovers intrinsic factors influencing CAR-T cell success

Research uncovers intrinsic factors influencing CAR-T cell success

Researchers uncover the link between EVs and tissue damage

Researchers uncover the link between EVs and tissue damage

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.